EP2288361A1 - Extrait de ciste contenant des ingrédients végétaux secondaires enrichis - Google Patents

Extrait de ciste contenant des ingrédients végétaux secondaires enrichis

Info

Publication number
EP2288361A1
EP2288361A1 EP09742098A EP09742098A EP2288361A1 EP 2288361 A1 EP2288361 A1 EP 2288361A1 EP 09742098 A EP09742098 A EP 09742098A EP 09742098 A EP09742098 A EP 09742098A EP 2288361 A1 EP2288361 A1 EP 2288361A1
Authority
EP
European Patent Office
Prior art keywords
extract
cistus
extraction
preparation
polyphenols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP09742098A
Other languages
German (de)
English (en)
Other versions
EP2288361B1 (fr
Inventor
Björn FEISTEL
Bernd Walbroel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Finzelberg GmbH and Co KG
Original Assignee
Finzelberg GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Finzelberg GmbH and Co KG filed Critical Finzelberg GmbH and Co KG
Priority to EP20090742098 priority Critical patent/EP2288361B1/fr
Publication of EP2288361A1 publication Critical patent/EP2288361A1/fr
Application granted granted Critical
Publication of EP2288361B1 publication Critical patent/EP2288361B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to enriched extracts of rock roses and preparations prepared therefrom, to processes for their preparation and to their use.
  • Cistus In the family of Cistaceae the Cistus (Cistus) form a genus of 18 to 20 species.
  • the subgenus Cistus creticus L. ssp. Eriocephalus grows up as an aromatic-scented evergreen shrub to Im. Its alternate, ovate-lanceolate leaves and radial symmetric, Uberescn flowers are common for the whole family, the pink, often pink to light purple color of the flowers is indicative of this subgenus.
  • Preferred habitat is the eastern Mediterranean.
  • eriocephalus finds a familiar pattern: similar to green tea extracts, catechin derivatives such as epigallocatechin or epigallocatechin gallate (EGCG) are found in the region of the valuable oligomer fractions.
  • EGCG epigallocatechin or epigallocatechin gallate
  • the total content of polyphenols in the plant is generally stated as 4%, but the proportion in the leaves is significantly higher.
  • Polyphenols are commonly known for their antioxidant behavior. This is the potential for trapping free radicals. In the human body it is especially "reactive oxygen species” that are produced environmental influences (UV radiation, chemical noxae) or one-sided, incorrect nutrition can occur to a particularly high degree. According to current scientific knowledge, many diseases are associated with “reactive oxygen species", since the cell damage caused by these radicals can trigger a variety of diseases (eg immune diseases, mental exhaustion, arthritis), if they are not limited by "antioxidant radical scavengers”. Therefore, the measurement of antioxidant capacity often provides trend-setting values. High polyphenol content indicates high antioxidant potential.
  • Cistus Incanus capsules LR Health & Beauty Systems
  • simple aqueous extracts (20-25% polyphenols, drug extract ratios 2-4: 1) represent the current state of the art.
  • Our own investigations confirmed the aqueous extractions of Cistus incanus ssp. tauricus or Cistus creticus eriocephalus can provide extracts with 20-28% polyphenols depending on the herb quality used.
  • the object of the invention was to provide a method for producing a high content cistus herb extract which reproducibly yields standardized extracts, preferably with at least 40% (m / m) polyphenols.
  • the object is achieved by a method for producing an extract of Cistus L. with the following steps:
  • Desirable for such a manufacturing process is a nearly constant quality of the vegetable feedstock. This is achieved by analysis of polyphenol contents (determined by means of Folin reagent and calculated as gallic acid analogous to the method of the European Pharmacopoeia, Chapter PH EUR (2.8.14)) and mixing of batches.
  • the drug is subjected to grinding and air classification in order to achieve an enrichment of the leaf material with respect to stem portions.
  • the leaves have higher levels of polyphenols. This achieves an improvement of about 30%.
  • Cistus creticus L. ssp eriocephalus is preferred.
  • Above-ground plant parts are preferably used.
  • starting material with a content of min. 12% polyphenols are preferred.
  • Suitable extractants are in particular water, methanol, ethanol, 1-propanol, 2-propanol and mixtures thereof.
  • a hydrous extractant is preferred.
  • the content of alcohol is preferably not more than 50% (V / V), preferably not more than 40% (V / V) or not more than 30% (V / V).
  • the extraction is carried out at an elevated temperature. Temperatures of 40 to 80 0 C are particularly preferred to achieve a particularly high Polyphenolausbeute.
  • the drug residue is usually removed; This can be done, for example, by filtering or aspirating and then squeezing the drug residue. Further possibilities are known to the person skilled in the art.
  • the extractant is at least partially removed from the resulting extract. This can be done, for example, by stripping off the solvent in a rotary evaporator or with the aid of a plate evaporator. Gentle treatment is preferred.
  • the dry matter content of the remaining extract is preferably more than 50% (m / m).
  • the remaining residue is redissolved.
  • water or mixtures of water with alcohol are particularly suitable for the redissolution.
  • the re-solvent contains at least 50% (m / m) of water.
  • the residue contains at least part of the tannins (low bioactive polyphenols). This is followed by an enrichment step. For this purpose, either a two-phase extraction or a membrane filtration can be used.
  • the two-phase extraction may be a liquid-liquid extraction.
  • extractant for the liquid-liquid extraction in particular n-butanol has been proven.
  • a solid-phase extraction can also be carried out. Extraction with adsorber resins is particularly suitable.
  • Typical adsorbent resins are, for example, nonionic hydrophobic divinylbenzene copolymers, aliphatic ester polymers and formophenol polymers. Such adsorbents are commercially available under the tradename Amberlite ®. Suitable products are the types of XAD2, XAD4, XAD7HP, XAD16, XAD761 or XADl but can be 180. Also uses analog characterized resins from other manufacturers as of Messrs. Diaion (SP Series), of Messrs. Bayer (Lewatite.RTM ®) or Fa Miontech (P series).
  • the type of resin Amberlite ® XAD7HP is particularly preferred.
  • membrane filtration may be performed.
  • Porous materials made of polyester sulfane, polypropylene, polytetrafluoroethylene or cellulose acetate are particularly suitable as membranes. Suitable pore sizes are 70-100 kD. These membranes can be used as multiple, superimposed filters in filter plates. This leaves about 60% of the polyphenols in the retentate (enriched product phase). Polyestersulfane membranes are particularly preferred.
  • the polyphenol-containing aqueous phase is treated with an organic solvent such as n-butanol.
  • the polyphenol substances pass into the organic phase through intensive mixing, and the organic phase is further worked up.
  • the polyphenols remain selectively on the solid phase before they can be eluted and separated by an elution change to more lipophilic solvents such as ethanol as a liquid phase, the organic phase is further worked up.
  • the extract is freed of its solvent in vacuo and can be dried to obtain a dry extract.
  • the drying should be carried out as gently as possible.
  • the invention also provides the extract obtainable by the process.
  • the extract is characterized by at least one of the following properties:
  • the cistus extract according to the invention mediates its action via an inhibition of NF- ⁇ B.
  • NF-KB is an important specific transcription factor, has numerous target genes and mediates different effects.
  • the activation of NF-KB is considered critical for the development of inflammation. Due to its diverse functions, NF- ⁇ B is also associated with numerous diseases Related. It is often unclear to what extent the activation of NF- ⁇ B actually intervenes causally in the disease process. Such a role is increasingly considered to be likely in some types of cancer, so that components of the NF- ⁇ B signaling pathway have become important targets for the development of new drugs.
  • NF- ⁇ B can bind to a specific DNA motif of about ten base pairs, the so-called ⁇ B motif. The binding of NF- ⁇ B to the DNA motif leads in most cases to an increased transcription of the genes dependent thereon.
  • NF- ⁇ B NF- ⁇ B regulated genes. These include many cytokines (eg, TNF- ⁇ and IL-1 ⁇ ) and adhesion molecules that play an important role in the regulation of the immune system, especially in inflammatory reactions.
  • cytokines eg, TNF- ⁇ and IL-1 ⁇
  • adhesion molecules that play an important role in the regulation of the immune system, especially in inflammatory reactions.
  • NF- ⁇ B include i.a. viral antigens (eg, lipopolysaccharides). Allergic-inflammatory reactions also proceed via this NF- ⁇ B signaling cascade and can likewise be reduced by an inhibiting influence.
  • viral antigens eg, lipopolysaccharides
  • A549 lung cells As a test model so-called A549 lung cells were used.
  • the effects of the cistus extract according to the invention on the transcriptional activity of NF- ⁇ B were investigated.
  • the cell system was coupled with a luciferase measuring system. After determining the blank values, the synthetic substance PMA was added as a stimulus, which significantly increases luciferase gene expression in A549 cells.
  • This system was fed the Cistus extract in various doses. A significant dose-dependent inhibition was found.
  • the AP-I binding site was also examined for specificity. After addition of an AP-I Luc plasmids for measuring luciferase activity were given the following results.
  • NF- ⁇ B itself provides an effect mediation on the tumor necrosis factor-alpha (TNF-alpha) known from anti-inflammatory investigations.
  • TNF-alpha tumor necrosis factor-alpha
  • Cistus extract influences a NF- ⁇ B-induced activation of TNF-alpha (canonical way).
  • a cloned 5.1 cell line was used in which there was a luciferase gene of H IV-I-LTR promoter. The cells were preincubated with increasing extract dosage and stimulated for 6 hrs with TNF cells. Subsequently, the cells were separated and reporter activity measured in the luciferase model.
  • a dose-dependent inhibition of TNFalpha-dependent HIV-1 LTR gene transcription could be determined (see FIG. 1).
  • the extract according to the invention with> 40% polyphenols proved to be significantly more potent than an aqueous extract containing> 20% polyphenols (prior art).
  • the invention also provides an extract preparation containing the extract according to the invention.
  • the invention also provides a pharmaceutical preparation or a food / nutritional supplement containing the extract according to the invention or the extract preparation according to the invention.
  • the first contact of a virus with the potential host usually takes place via the mucous membranes. Accordingly, a local application on the mucous membranes to good results.
  • the application in diseases such as nasal mucosa, paranasal sinus, laryngeal or vocal cord inflammation, which often accompany a common cold, as effective.
  • cistus extracts produced according to the invention have a high inhibitory effect on the neuraminidase activity.
  • Neuraminidases are a family of enzymes of influenza (type A and B) and other viruses that cleave terminal sialic acid residues from the cell surface glycoproteins of virus host cells and the viruses themselves. This process promotes the release of daughter viruses from the infected cells.
  • So-called neuraminindase inhibitors are drugs that slow this process of cleavage from the host cell after a viral infection and thus reduce the (systemic) free viral load. In general, it is important to take the drug within a very short time after the first symptoms, because at this time the body's own immune defense is not yet exhausted and becomes more efficient by a medical reduction of the viral load.
  • This type of drug includes Tamiflu ® (oseltamivir) and Relenza ® (zanamivir), which is hoping to provide initial mitigation in the event of a possible bird flu virus H5N1 pandemic.
  • Tamiflu ® oseltamivir
  • Relenza ® zanamivir
  • these chemical neuraminidase inhibitors often have side effects such as nausea, stomach pain, and vomiting.
  • initial resistance to these drugs is now being observed.
  • Cistus extract compared to zanamivir was in an in vitro -Enzymmodell (NA-Star ®) according Wetherall NT, Trivedi T, Zeller J, Hodges -Savola C, McKimm-Breschkin JL, Zambon M, Hayden FG. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. Clin Microbiol. 2003 Feb; 41 (2): 742-50. tested.
  • a virus suspension is mixed with extract and the infectivity of the viruses in cells is measured.
  • As a positive control ethanol is used.
  • the determination of the virustatic activity is determined by the virus titer in the supernatant of infected human cells after inoculation with extract. Acknowledged positive control is acyclovir.
  • postviral fatigue syndrome such as Royal Free Disease, Myalgic Encephalomyelitis, Epidemic Neuromyasthenia, Chronic Mononucleosis, Chronic Epstein-Barr Virus Disease, Chronic Fatigue Syndrome or Short Postviral Syndrome.
  • Current research indicates that the disease could be caused by specific viruses, such as the Epstein-Barr virus, the Cause of Pfeiffer's glandular fever.
  • the symptoms usually develop slowly after the onset of an acute infection (often with fever, shivering, body pain, swollen lymph nodes and fatigue). After the illness seems to have faded, the patient begins to feel unwell again and various symptoms remain constant from that point onwards.
  • the main symptoms are marked weakness and pain in the muscles, memory and concentration deficiency, fatigue and a persistent or recurring general flu-like feeling.
  • influenza also H5N1 and HlNl
  • herpes simplex infections are also H5N1 and HlNl.
  • the zistrosis extract preparations according to the invention have an inhibiting effect on the NF-kB signal transduction and can be used in (local) allergic-inflammatory reactions in the ENT range. Due to the extract activity as a neuraminidase inhibitor, corresponding extract preparations can also be used for the treatment and prophylaxis of rhinitis and sinusitis as well as against postviral fatigue states.
  • tinctures As a dosage form for the application of the extract according to the invention are in particular tinctures, syrups, brushings, gargle solutions, (nose) drops, nasal sprays and inhalation or inhalable powder.
  • dried forms of the extract according to the invention are suitable for conventional use in capsules, tablets, dragees, lozenges, lozenges or chewable tablets or in the form of redissolved powders, granules or effervescent preparations.
  • an orodispersible tablet or lyophilisates are suitable as a dosage form around locally fast To have a high concentration available.
  • FIG. 1 shows effects of cistus extracts on TNF ⁇ -induced NF-kappaB transcription.
  • FIG. 2 shows an HPLC fingerprint of the extract according to Example 5.
  • Binary high pressure gradient system e.g. B. consisting of:
  • the starting drug used are the renewable aerial parts (leaves, flowers, stems), which are gently dried, comminuted to an extraction size of about 10 mm and depleted of the stalk components by air classification.
  • This method is based on a redox reaction with the stable 2,2-diphenyl-1-picrylhydrazyl radical (DPPH).
  • DPPH 2,2-diphenyl-1-picrylhydrazyl radical
  • the ability of extracts to act as a direct antioxidant can be determined.
  • the DPPH radical has a violet coloration due to the unpaired electron on the nitrogen atom. The color changes from purple to yellow when the radical enters into a bond with a hydrogen atom of a radical scavenger and the reduced DPPH-H (2,2-diphenyl-l-picrylhydrazine) is formed.
  • photometric determination of the reduction in absorption at 517 nm the antioxidant effect of isolated substances or plant extracts can be quantified. Indicated is the 50% inhibition value.
  • aqueous extracts of the species Cistus creticus L. are superior to the other species in terms of their antioxidant potential.
  • Particularly potent are extracts of the subspecies Cistus creticus L. ssp. Eriocephalus.
  • the supernatant (product phase) is withdrawn from above and clear filtered through a CPIKS filter plate (quantitative yield 95%).
  • the polyphenol content was 32.0% based on the native extract.
  • the extract solution according to Ex. 4, containing 3.58 kg of native extract as about 20% solution, is applied to a column filled with 5OL adsorbent resin (Amberlite® XAD7HP). The run is separated and discarded. The column is then rinsed clean with 3 bed volumes (150 L) of water. Elution of the adsorbed secondary cistus ingredients is done with 100 L ethanol 96% (v / v). The ethanolic-aqueous eluate is collected, clarified by filtration and freed from the solvent by means of a vacuum concentration and evaporated to the spissum. This resulted in 2 kg of spissum with a dry matter content of 65% ( 1.3 kg of native extract). The polyphenol content was 65.0% based on the native extract. The monomer content (Theogallin, Epigallocatechin, Catechin, Epicatechin and Epigallocatechningallat) is 3.6%.
  • the extract is characterized by a specific HPLC fingerprint (see Fig. 2).
  • Spissum extract obtainable according to Ex. 5 is subjected to spray drying.
  • the spissum is adjusted to 40% dry matter content in water and fed to a spray tower with 180 0 C inlet temperature. After misting in the tower, a fine powder is produced, which causes the Tower in the air stream at 100 0 C leaves.
  • the product temperature of the extract does not exceed 55 ° C.
  • the result is a fine powder (95% ⁇ 0.315 mm) with a drying loss of 4%.
  • the polyphenol content was 64.8% based on the native extract.
  • spissum extract obtained according to Ex. 3 100 g are dissolved with demineralized water back to 5% dry matter content and freed from suspended matter. It is then adjusted to a pH in the range of 4.5 - 5.0.
  • This solution is separated into two fractions by tangential flow filtration over a 100 kD membrane (polyethersulfane) for 2 hours. This forms a filtered permeate phase and a retained retentate phase.
  • the polyphenol accumulation in the retentate proceeds specifically and gives significantly higher contents than the quantity distribution would suggest. Compared to the feed extract with 31.4% polyphenols, the content could be increased by 42%.
  • retentate phase 100 g of native extract according to Ex. 3 (retentate phase) is adjusted to 20% dry matter content in water. The mixture is then mixed thoroughly at room temperature 3 times with 1/3 volume of n-butanol in a separating funnel. After a 30 min life, a clear phase separation forms. The n-butanol phase is separated from the aqueous phase.
  • ORAC Oxygen Radical Absorption capacity
  • Cistus extract according to the invention 5100 ⁇ mol TE / g
  • Aqueous Cistus extract (25% polyphenols) 1900 ⁇ mol TE / g
  • the enriched according to the invention Cistus extract with 60% polyphenols has an extraordinarily high ORAC potential that is increased over the prior art by a factor of 2.7.
  • the accumulation of polyphenol-containing ingredients from Herba Cistus L. correlates with the antioxidant potential.
  • Aqueous Cistus extract (25% polyphenols): 20.5 ⁇ 9.3% Vitamin C (method standard): 96.6 ⁇ 11.3%
  • Cistus extract with 60% polyphenols has an extremely high antioxidant capacity in the inactivation of free oxygen radicals, which is increased over the prior art by a factor of 3.2.
  • the purified ethanolic extract obtained according to Ex. 5 is redissolved with water to a dry matter content of 12%. This is followed by the addition of 20% glycerol with stirring. Thus, a drop formulation is obtained which has improved taste and has been preserved for longer.
  • Example 11 Application as a nose drop
  • the drop formulation prepared according to Ex. 10 above used a male subject of 38 years nasally in the form of drops from a pipette bottle in the course of a very severe acute hay fever attack. After only a few minutes, the mucous membranes had shrunk to a normal level.
  • the drop formulation prepared according to Ex. 10 above used a male subject of 56 years, in the course of a very severe acute hay fever attack, nasally in the form of a finely dusted dropper dosage from a nebulizer. Through this spray dosage a reduction of the Schnupfattacken was achieved within a few minutes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé de fabrication d'un extrait contenant au moins 40 % (m/m) de polyphénols issus de Cistus creticus L., comportant les étapes suivantes: extraction de fractions végétales de Cistus creticus L. au moyen d'un agent d'extraction choisi dans le groupe comportant l'eau, des alcools et des mélanges de ceux-ci; élimination de résidus d'extraction; élimination au moins partielle de l'agent d'extraction; dissolution inverse dans un solvant aqueux et élimination de constituants insolubles; et enrichissement sélectif au moyen d'au moins une des étapes a) extraction biphase et b) filtration par membrane.
EP20090742098 2008-05-06 2009-05-06 Extrait de ciste contenant des ingrédients végétaux secondaires enrichis Active EP2288361B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP20090742098 EP2288361B1 (fr) 2008-05-06 2009-05-06 Extrait de ciste contenant des ingrédients végétaux secondaires enrichis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08155699 2008-05-06
EP20090742098 EP2288361B1 (fr) 2008-05-06 2009-05-06 Extrait de ciste contenant des ingrédients végétaux secondaires enrichis
PCT/EP2009/055487 WO2009135880A1 (fr) 2008-05-06 2009-05-06 Extrait de ciste contenant des ingrédients végétaux secondaires enrichis

Publications (2)

Publication Number Publication Date
EP2288361A1 true EP2288361A1 (fr) 2011-03-02
EP2288361B1 EP2288361B1 (fr) 2013-08-21

Family

ID=40282426

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20090742098 Active EP2288361B1 (fr) 2008-05-06 2009-05-06 Extrait de ciste contenant des ingrédients végétaux secondaires enrichis

Country Status (4)

Country Link
US (1) US9173912B2 (fr)
EP (1) EP2288361B1 (fr)
MX (1) MX2010011922A (fr)
WO (1) WO2009135880A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2575844B1 (fr) * 2010-05-28 2016-11-23 Finzelberg GmbH & Co. KG Procédé de fabrication d'un extrait enrichi constitué de feuilles de vignes
DE102010055170A1 (de) * 2010-12-20 2012-06-21 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Verfahren zur Herstellung alkoholfreier Zusammensetzungen auf pflanzlicher Basis sowie auf diese Weise hergestellte Zusammensetzungen und deren Verwendung
EP2844263A1 (fr) * 2012-05-04 2015-03-11 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Extrait de plante pour le traitement d'une infection par le vih et produits associés à celui-ci
CN103948857A (zh) * 2014-05-13 2014-07-30 黄业武 一种慢性鼻窦炎鼻内镜术后的药物组合物
CN104162131A (zh) * 2014-08-13 2014-11-26 刘建煌 一种用于治疗鼻炎的药茶
DE102016002873A1 (de) 2016-03-09 2016-05-25 Heinz Kiefer Zellnachweisverfahren und Screeningverfahren von Stoffbibliotheken zur Identifizierung von Einzelstoffen, die im Falle einer bioterroristischen Bedrohung gegen Mischungen synthetischer Viren wirksam sind
CN108542987A (zh) * 2018-07-06 2018-09-18 邵显武 一种治疗鼻炎的中药组合物及其制备方法
TR2022000292A2 (tr) 2022-01-11 2022-02-21 Tuerkiye Bilimsel Veteknolojik Arastirma Kurumu SARS-CoV-2 Virüsüne Karşı Koruyucu Pastil/Çiğneme Tableti Üretimi
WO2024046653A1 (fr) 2022-08-29 2024-03-07 Mycotech Pharma As Extraits fongiques antiviraux

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2416979C3 (de) 1974-04-08 1978-10-12 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Verfahren zur Gewinnung des in den Wurzeln und Rhizomen von Helleborus-Arten enthaltenen Hauptsapogenins
GB9104286D0 (en) 1991-02-28 1991-04-17 Phytopharm Ltd Pharmaceutical compositions for the treatment of skin disorders
JPH06336421A (ja) 1993-05-28 1994-12-06 Kose Corp 皮膚外用剤
CN1102993A (zh) 1993-12-21 1995-05-31 吴文才 多酶体系加工中草药的制剂方法
DE59710082D1 (de) 1996-12-13 2003-06-18 Vesifact Ag Baar Kosmetische Präparate in Form einer Nanodispersion
US6024960A (en) 1998-04-17 2000-02-15 Otto Torbjorn Hansen And Marianne Hansen Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis
US6576275B1 (en) * 1999-02-02 2003-06-10 Archer-Daniels-Midland Company Process for extracting polyphenolic antioxidants from purine-containing plants
WO2000064883A1 (fr) 1999-04-23 2000-11-02 Kyowa Hakko Kogyo Co., Ltd. Methodes de purification d'oligomeres de proanthocyanidine
JP2001072583A (ja) 1999-09-07 2001-03-21 Sunstar Inc 高脂血症の予防又は治療用組成物
JP4726022B2 (ja) 2000-03-28 2011-07-20 キッコーマン株式会社 抗アレルギー、抗炎症剤並びにこれを含有する医薬組成物、医薬部外品、化粧品、食品及び動物用飼料
US6485752B1 (en) 2000-10-23 2002-11-26 Otto Torbjorn Hansen Composition and method for alleviating joint pain and stiffness
WO2003043613A2 (fr) 2001-11-21 2003-05-30 Danmarks Jordbrugsforskning Utilisation des glycosides de mono- et diacylglycerol comme agent anti-inflammatoire
JP2004113141A (ja) 2002-09-26 2004-04-15 Daawinzu:Kk Ｍｓｍ含有の健康食品
WO2004080993A1 (fr) * 2003-03-11 2004-09-23 Toyo Shinyaku Co., Ltd. Procede de production d'une matiere riche en proanthocyanidine
RU2240131C1 (ru) 2003-04-04 2004-11-20 Аладьев Сергей Иванович Средство "артровит" для профилактики и лечения артритов и артрозов
CN1928098A (zh) 2005-09-06 2007-03-14 童志清 一种精制番茄红素的方法
CA2622508C (fr) * 2005-09-13 2013-06-25 Georgios Pandalis Medicament pour la prevention et le traitement de la grippe
US8017162B2 (en) 2005-10-26 2011-09-13 Oryza Oil & Fat Chemical Co., Ltd. Anti-inflammatory agent
FR2897238A1 (fr) 2006-02-15 2007-08-17 Novasep Soc Par Actions Simpli Procede de purification de la thaumatine
DE202006004872U1 (de) 2006-03-10 2006-07-20 Icb Investment Consulting Und Beteiligungen Gmbh Mittel zur oralen Einnahme
ES2314772T3 (es) 2006-03-24 2009-03-16 Georgios Pandalis Composicion para la prevencion y tratamiento de afecciones catarrales.
JP2007261987A (ja) 2006-03-28 2007-10-11 Sanki Shoji Kk チロシナーゼ阻害剤、その製法およびその応用
JP2009541371A (ja) 2006-07-03 2009-11-26 ヒーベン・ビタル・ライセンス・アンパルトセルスカブ モノまたはジアシルグリセロール生成物のグリコシドを植物性材料から製造する方法
KR20090033470A (ko) 2006-07-14 2009-04-03 디에스엠 아이피 어셋츠 비.브이. 로즈힙 및 다른 활성 약품을 포함하는, 염증성 질환의 치료를 위한 조성물
WO2008037707A2 (fr) 2006-09-27 2008-04-03 Finzelberg Gmbh & Co. Kg Préparation d'un extrait de valériane
ES2539453T3 (es) 2007-12-21 2015-07-01 Finzelberg Gmbh & Co. Kg Preparaciones con extractos de escaramujo así como procedimientos para la preparación de extractos de escaramujo
RU2355240C1 (ru) 2008-01-09 2009-05-20 Федеральное государственное образовательное учреждение высшего профессионального образования "Калининградский государственный технический университет" Способ получения пищевого препарата хондропротекторного действия
EP2130443A1 (fr) 2008-06-06 2009-12-09 Finzelberg GmbH & Co. KG Extraits solubles dans l'eau d'Artemisia dracunculus (estragon) pour l'amélioration du métabolisme de glucose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009135880A1 *

Also Published As

Publication number Publication date
US9173912B2 (en) 2015-11-03
EP2288361B1 (fr) 2013-08-21
US20110059190A1 (en) 2011-03-10
MX2010011922A (es) 2011-03-02
WO2009135880A1 (fr) 2009-11-12

Similar Documents

Publication Publication Date Title
EP2288361B1 (fr) Extrait de ciste contenant des ingrédients végétaux secondaires enrichis
KR20220156605A (ko) 중약 조성물의 코로나 바이러스 감염 치료 또는 예방 약물 제조에서의 응용
CN114246925A (zh) 一种中药精油及其应用
CN107753660B (zh) 一种具有抑制乙酰胆碱酯酶活性的沉香提取物及其应用
CN108113962A (zh) 一种降低含有多酚的中药口服制剂涩味的方法
EP1651244B1 (fr) Utilisation d'extraits de racines de Pélargonium sidoides et/ou Pélargonium réniforme
DE19823679C2 (de) Verwendung von Crataegus-Zubereitungen zur Prophylaxe und Therapie neoplastischer Erkrankungen
WO2020194122A1 (fr) Produits pour inhalation à base de cannabis et procédés de production de ces derniers
WO2003028746A1 (fr) Procede d'obtention d'extraits de pelargonium sidoides et/ou pelargonium reniforme, et utilisation de ces extraits
WO1999051250A1 (fr) Utilisation d'extraits d'echinacea pallida et d'echinacea angustifolia; extraits de dents de lion (taraxacum); extraits de plantain (plantago)
WO2022135329A1 (fr) Composition pharmaceutique contenant erigerontis herba, ginseng radix et rhizoma, ophiopogonis radix et schisandrae chinensis fructus
RU2213570C2 (ru) ЛЕЧЕБНО-ПРОФИЛАКТИЧЕСКОЕ СРЕДСТВО ИЗ ЛИСТЬЕВ ЛИПЫ Folia Tilia И СПОСОБ ПОЛУЧЕНИЯ ЭКСТРАКТИВНЫХ ВЕЩЕСТВ
Tadesse et al. Preliminary phytochemical screening of different solvent extracts of leaves and stems of Commelina benghalensis L.(Family: Commelinaceae)
Kommu Phytochemical Screening and Quantitative Determination of Phytochemicals in Hydro alcoholic extract of Cleome gynandra L. Whole plant
RU2032419C1 (ru) Гепатозащитное средство и способ его получения
Ramteke et al. PHYTO-PHARMACOGNOSTIC SCREENING AND IN-VIVO ANTIUROLITHIATIC ACTIVITY OF STIGMA OF ZEA MAYS LINN.
RU2576238C1 (ru) Сбор лекарственных растений для лечения функционального расстройства желчного пузыря при гипертонически-гиперкинетическом типе дискинезии
EP1644015B1 (fr) Procede d'extraction vegetale et extrait
AT400673B (de) Verfahren für die herstellung von heilpflanzenextrakten
RU2526165C1 (ru) Ресурсосберегающий способ получения сухого экстракта из коры коричника цейлонского
DE102004003801A1 (de) Verfahren zur Gewinnung des Stoffes Melanin und Verwendung des Verfahrensproduktes
WO2002030436A1 (fr) Procede de production d'extraits de phyllanthus
Revathi et al. PHYSICOCHEMICAL AND PHYTOCHEMICAL ANALYSIS OF TRIPHALA IN AQUEOUS AND METHANOLIC EXTRACTS
RU2182487C2 (ru) Способ получения средства, обладающего гипотензивной активностью
Ananthi A Toxicity study on Manosilai Chooranam

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20110726

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 627651

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502009007833

Country of ref document: DE

Effective date: 20131017

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20130821

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130918

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131221

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131223

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131121

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131122

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20140522

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502009007833

Country of ref document: DE

Effective date: 20140522

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140506

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20140506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140531

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140531

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20150130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140506

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140602

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20150430

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20150520

Year of fee payment: 7

Ref country code: IT

Payment date: 20150519

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140531

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20090506

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 627651

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160506

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160506

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20170529

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130821

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 502009007833

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181201